PT  - JOURNAL ARTICLE
AU  - Vanessa L. Cropley
AU  - Masahiro Fujita
AU  - John L. Musachio
AU  - Jinsoo Hong
AU  - Subroto Ghose
AU  - Janet Sangare
AU  - Pradeep J. Nathan
AU  - Victor W. Pike
AU  - Robert B. Innis
TI  - Whole-Body Biodistribution and Estimation of Radiation-Absorbed Doses of the Dopamine D<sub>1</sub> Receptor Radioligand <sup>11</sup>C-NNC 112 in Humans
DP  - 2006 Jan 01
TA  - Journal of Nuclear Medicine
PG  - 100--104
VI  - 47
IP  - 1
4099  - http://jnm.snmjournals.org/content/47/1/100.short
4100  - http://jnm.snmjournals.org/content/47/1/100.full
SO  - J Nucl Med2006 Jan 01; 47
AB  - The present study estimated radiation-absorbed doses of the dopamine D1 receptor radioligand [11C]((+)-8-chloro-5-(7-benzofuranyl)-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine) (NNC 112) in humans, based on dynamic whole-body PET in healthy subjects. Methods: Whole-body PET was performed on 7 subjects after injection of 710 ± 85 MBq of 11C-NNC 112. Fourteen frames were acquired for a total of 120 min in 7 segments of the body. Regions of interest were drawn on compressed planar images of source organs that could be identified. Radiation dose estimates were calculated from organ residence times using the OLINDA 1.0 program. Results: The organs with the highest radiation-absorbed doses were the gallbladder, liver, lungs, kidneys, and urinary bladder wall. Biexponential fitting of mean bladder activity demonstrated that 15% of activity was excreted via the urine. With a 2.4-h voiding interval, the effective dose was 5.7 μSv/MBq (21.1 mrem/mCi). Conclusion: 11C-NNC 112 displays a favorable radiation dose profile in humans and would allow multiple PET examinations per year to be performed on the same subject.